TNP-470对小鼠肝癌H22腹水瘤的治疗研究

The effect of TNP-470 treatment on ascitic-fluid type hepatocarcinoma H22

目的探讨TNP-470治疗小鼠肝癌H22腹水瘤的疗效及机制。方法体外采用细胞增生法和迁移法探讨TNF-470的治疗机制;体内建立H22腹水瘤小鼠模型评价TNP-470的疗效。结果TNP-470对瘤细胞H22的增生、血管内皮细胞HMEC的增生和迁移都有抑制作用;能明显提高小鼠生活质量、降低腹水的产生和瘤细胞的存活率及小鼠失明率,延长生存期。结论TNP-470对荷H22腹水瘤小鼠有明显疗效。

Objective To study the effect of TNP-470 treatment on ascitic hepatocarcinoma H22 and potential mechanisms. Methods The experimental approaches employed in the study included in vitro assays of cell proliferation and migration, and in vivo ascitic hepatocarcinoma mouse model. Results In vitro, TNP- 470 inhibited cell proliferation of both H22 and human microvascular endothelial cell HMEC. Furthermore, TNP-470 inhibited HMEC migrations. In vivo, TNP-470 treatment significantly improved the life quality of the tumor-loaded mice, including lessen the ascitic effasion, decreased tumor cell viability, lessen the eye blindness, and prolonged the life-span. Conclusion These observations demonstrate that TNP-470 would be an effective drug for treatment of ascitic-fluid type hepatocarcinoma mice.